Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with Angioimmunoblastic T-cell lymphoma (AITL) according to the 2016 WHO classification, and who have at least one measurable area of disease (a lymph node larger than 1.5 cm, or a non-lymph node affected area larger than 1.0 cm).
• People whose AITL has come back or stopped responding after at least one previous treatment, such as chemotherapy or a stem cell transplant.
• People aged 18 or older, of any sex, who are well enough to carry out some daily activities (confirm with trial site regarding the specific fitness scale used).
• People who are expected to live for more than 3 months.
• People who are willing and able to attend follow-up appointments and understand what taking part in the study involves.

Who may not be able to join:

• People with significantly abnormal liver or kidney function test results (more than twice the normal range), unless the trial site considers this to be caused directly by the lymphoma.
• People whose blood counts are too low — specifically, low white blood cells, low platelets, or low haemoglobin — unless the trial site considers this to be caused by lymphoma affecting the bone marrow.
• People who have previously received certain treatments, including: the chemotherapy drug mitoxantrone (or its liposome form); PD-1 or PD-L1 immunotherapy drugs; or a type of drug called a histone deacetylase inhibitor for this condition.
• People with serious heart problems, including severe heart failure, a weakened pumping function of the heart (ejection fraction below 50%), or certain heart conditions within the past 6 months such as a heart attack, severe heart failure, or problems with heart rhythm (confirm with trial site for full details).
• People who have HIV/AIDS, active syphilis, active hepatitis B (with viral levels above a certain threshold), or hepatitis C.
• People who have another cancer that is not well controlled, or another blood disorder such as haemophilia or myelofibrosis, where the trial doctor considers participation unsuitable.
• People with a history of autoimmune disease who are currently taking immune-suppressing medications above a certain dose or for more than two weeks before joining.
• People with an active infection (bacterial, fungal, or viral) that is not responding to treatment.
• People with an uncontrolled condition called haemophagocytic syndrome (a serious immune system disorder).
• People who have had major surgery within 3 weeks before starting treatment.
• People who have taken part in, or are currently participating in, another clinical drug trial within the 30 days before joining.
• Women who are pregnant or breastfeeding, or people of childbearing age who are not willing to use contraception.
• People with a known allergy to any component of the study drug.
• People whom the trial doctor considers unsuitable for enrolment for any other reason.

Important: Always verify eligibility with the trial site directly before applying.